2025年12月,Nona生物科学组织任命Hongjiang Miao博士为第一任AI首席官员,以推进AI驱动的药物发现。 Nona Biosciences appoints Dr. Hongjiang Miao as first Chief AI Officer in December 2025 to advance AI-driven drug discovery.

自2025年12月起,Nona生物科学组织已任命Hongjiang Miao博士为首任AI首席干事,负责在其药物发现平台上领导AI的整合工作。 Nona Biosciences has named Dr. Hongjiang Miao its first Chief AI Officer, effective December 2025, to lead AI integration across its drug discovery platforms. Miao博士将开发AI驱动的研究工具,加强数据系统,建立可扩展的AI研发平台,以此推进该公司的A3战略,即结合抗体工程、人工智能和自动化。 Based in Shanghai, Dr. Miao will advance the company’s A³ strategy—combining antibody engineering, artificial intelligence, and automation—by developing AI-driven research tools, enhancing data systems, and building a scalable AI R&D platform. 他在蛋白质结构预测和人工智能产生的蛋白质设计方面的专长是通过在Great Bay Bio和Tianrang Intell公司以前的角色获得的,支持诺娜加速精密药品开发的目标。 His expertise in protein structure prediction and AI-generated protein design, gained through prior roles at Great Bay Bio and Tianrang Intelligence, supports Nona’s goal of accelerating precision medicine development. 任命标志着向AI动力生物创新的战略性转变。 The appointment marks a strategic shift toward AI-powered biologics innovation.